Yellwin Announces Completion of Nearly 100 Million Yuan in Series A+ Financing, Led by Noyou Capital with Participation from Central-South Venture Capital Fund and Qichen Holdings; Existing Shareholders IDG Capital and Wise Creation Ventures Continue to Increase Investment.
Yellwin, established in 2021, is an innovative enterprise dedicated to the research and development of devices in the field of cardiac surgery and heart failure. The company was co-founded by a team of clinical experts in cardiac surgery from Anzhen Hospital along with senior technical experts from the cardiovascular device industry both in China and abroad. The team has accumulated over 20 years of clinical and product development experience in cardiac surgery and heart failure. Starting from clinical needs, the team has been committed to creating products that not only meet the requirements of clinical work but also fill the market gap in related fields of medical devices in China. At the same time, these products align with national healthcare policy directions, helping to accelerate the innovation process of domestic high-end medical devices in China, enabling doctors to improve clinical outcomes while reasonably controlling medical costs.
Since its establishment, Yellwin has consistently focused on commercialization and innovation as the core drivers of product development. Currently, several products such as a new-generation heart stabilizer, femoral artery-vein catheters, and an intelligent coronary angiography scoring system are nearing registration approval and entering the commercial sales phase. The company has also strategically positioned multiple short-cycle, fast-commercialization projects in areas like animal experiments and nursing. Meanwhile, Yellwin is actively increasing investment in its key products: the coronary artery bypass quality control system has entered the experimental production stage, and the pulsatile left ventricular assist system has completed design finalization. These products will fill clinical gaps in China and accelerate the localization of high-end cardiovascular surgical medical devices.
Yellwin's self-developed pulsatile percutaneous left ventricular assist device (PVAD) was developed based on the clinical pain points in severe cardiac surgery, while also meeting the treatment needs of patients with cardiogenic shock in cardiology scenarios. Yellwin’s PVAD product not only offers the advantages of low cost, high safety, and no need for DSA assistance like IABP products, but also addresses the issue of insufficient flow found in traditional pulsatile PVAD products such as IABP and PulseCath. The product aims to complement continuous flow PVAD products represented by IMPELLA, providing Chinese cardiovascular physicians with a powerful, self-innovated tool made in China to manage high-risk patients.